English
Russian
The search for alternative therapy for chronic cystitis: results of a prospective comparative randomized study on the effectiveness of a biologically active complex «Cystalis® D Plus» DOI: https://doi.org/10.29188/2222-8543-2024-17-1-138-144
- Ibishev Kh.S. – Dr. Sc., Full Prof.; Prof., Dept. of Urology, Pediatric Urology and Reproductive Health, Rostov State Medical University; Rostov-on-Don, Russia; RSCI Author ID 645359; http://orcid.org/0000-0002-2954-842X
- Nashivochnikova N.A. – PhD, Associate Professor of the Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University Ministry of Health of Russia; Nizhny Novgorod, Russia; RSCI Author ID 980736, https://orcid.org/0000-0002-1138-1174
- Tsareva A.V. – PhD, urologist, «AVICENNA» Medical center, «Mother and Kid» company group; Novosibirsk, Russia; RSCI Author ID 630758, https://orcid.org/0000-0001-5139-8109
- Shaderkin I.A. – PhD, Head of the Laboratory of Electronic Health, Institute of Digital Medicine Sechenov University; Moscow, Russia; RSCI Author ID 695560, https://orcid.org/0000-0001-8669-2674
- Krasnyak S.S. – PhD, Leading Researcher, Andrology and Human Reproduction Unit, N. Lopatkin Scientific Research Institute of Urology and Interventional Radiology — branch of the National Medical Research Radiological Centre; Moscow, Russia; RSCI Author ID 641107, https://orcid.org/0000-0001-9819-6299
328 Introduction. Cystitis is one of the most prevalent urinary tract infection (UTI) type. An important specifity of cystitis is the tendency to relapse and chronization of the disease. The search for a safe and effective strategy for the treatment and prevention of recurrence of chronic cystitis is an extremely urgent problem.
The purpose of this study is to compare the effectiveness of Cystalis® D Plus with antibiotics treatment in chronic cystitis relapses treatment.
Materials and methods. The study included 120 patients with an established diagnosis of chronic cystitis at the moment of intensification. All patients were randomized into 4 groups: the first group received Cystalis® D Plus in monotherapy for 7 days, the second group received Cystalis® D Plus for 7 days together with nonsteroidal anti-inflammatory drugs (NSAIDs) in accordance with the recommendations, the third group received fosfomycin trometamol in accordance with the recommendations, the fourth group received fosfomycin trometamol together with NSAIDs in accordance with recommendations. All groups were monitored for a month after the start of therapy.
Results. Patients from all groups noted a significant decrease in intensity of pain according to VAS already on the third day of treatment. Also, there was a significant decrease in the symptoms of acute cystitis on thescale «Acute cystitis symptom score» (ACSS scale), a decrease in the number of leukocytes in the urine and a decrease in microbial load in all groups. All the positive changes in the groups were comparable to each other.
Conclusions. «Cystalis® D Plus» leads to rapid and persistent relief of symptoms of recurrent cystitis both in monotherapy mode and in combination with other groups of drugs.
| Attachment | Size |
|---|---|
| Download | 2.12 MB |
Other issue articles
